Pfizer Inc. $PFE Shares Bought by Tandem Investment Partners LLC

Tandem Investment Partners LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 13.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 11,615 shares of the biopharmaceutical company’s stock after purchasing an additional 1,385 shares during the quarter. Tandem Investment Partners LLC’s holdings in Pfizer were worth $282,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the 1st quarter worth $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter worth $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the 1st quarter worth $28,000. Horizon Financial Services LLC acquired a new position in shares of Pfizer in the 1st quarter worth $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer in the 1st quarter worth $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE opened at $27.37 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $155.59 billion, a PE ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The stock has a 50-day moving average of $24.67 and a 200-day moving average of $24.14. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business earned $0.60 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. UBS Group restated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday. Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.